narsoplimab   Click here for help

GtoPdb Ligand ID: 14317

Synonyms: narsoplimab-wuug | OMS-721 | OMS721 | Yartemlea®
Approved drug
narsoplimab is an approved drug
Compound class: Antibody
Comment: Narsoplimab (OMS721) is a fully human IgG4 monoclonal antibody against mannan-binding lectin-associated serine protease 2 (MASP-2) [2].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Narsoplimab was first approved by the US FDA in December 2025 [5], to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. Development as a therapy for other microangiopathies such as IgA nephropathy and atypical hemolytic uremic syndrome has been discontinued.

COVID-19: narsoplimab was evaluated to treat complement-mediated activation of the immune system and microangiopathic endothelial cell damage in patients with severe COVID-19 [1,4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy Phase 3 Interventional Omeros Corporation This study was terminated as narsoplimab treatment did not provide efficacy with respect to the prespecified primary endpoint.
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Phase 2 Interventional QuantumLeap Healthcare Collaborative
NCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2 Interventional Omeros Corporation
NCT02222545 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2 Interventional Omeros Corporation 3